Rifaximin SSD
Small molecule
Evidence outlook · registrational
Topline reported 2026-01
Its supporting mid-stage studies have completed. The sponsor reported topline results in 2026-01 (Phase 3 RED-C programmes (NCT05071716, NCT05297448): both failed their primary endpoints). The announcement is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
No investor-visible indication is recorded for this drug.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other Rifamycin Antibacterial drugs
Rifaximin (Xifaxan). Compare all 2 Rifamycin Antibacterial drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rifaximin SSD: this drug | Phase 3 | Small molecule | Rifamycin Antibacterial | not yet graded | No reviewed efficacy summary | |
| Rifaximin (Xifaxan) | Approved(overall) | Small molecule | Rifamycin Antibacterial | not yet graded | No reviewed efficacy summary |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Rifaximin SSD to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
October 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent